Taken together, these data suggest that STING plays an essential role in hematopoietic disorders induced by TET2 mutation and inhibition of STING represents a potential therapeutic strategy to block the production of inflammatory cytokines and mitigate the development of CH driven by TET2 mutations (Fig. 6). Here, TET2 is linked to cyclic hematopoiesis.